Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04549246 · ClinicalTrials.gov registry record
Grid Therapy for Tumors of the Head, Neck, Thorax, Abdomen, Pelvis and Extremities.
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 83
- Enrollment target
NCT04549246: Completed study, sponsored by Mayo Clinic.
NCT04549246 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 83 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04549246 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 83 participants
- Enrollment target
Study Summary
This study is an observational registry study evaluating the clinical outcomes of grid therapy. Subjects will be screened at outpatient clinic visit appointments and interested qualified subjects will be consented and offered participation in this study. Once consent has been obtained, baseline adverse event and QOL data will be collected and subjects will undergo grid therapy and follow-up at 2-4 weeks (for toxicity), and 3-6 months (for toxicities and radiographic control) then per clinical discretion up to 1 year. Patients will be evaluated according to the physician's standard practice and discretion. Patient data will be drawn from the patients' medical records and reported by means of a web-based electronic data collection (EDC) system. Patients will be considered "on study" until 60 months of observation has occurred, withdrawal of consent, lost to follow-up, or study closure. See below for the clinical visit flowchart for data collected at baseline and standard clinic visits.
Primary Outcome
Assessed according to Response Evaluation Criteria In Solid Tumors (RECIST), a standard system to measure how cancer responds to different treatments, including chemotherapy, immunotherapy, and radiation therapy. The local/radiographic control rate will be estimated overall and by palliative/definitive patient status in patients treated with grid therapy.
Interventions
- RADIATION Spatially Fractionated Radiation (GRID) Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2020-06-18 |
| Est. Completion | 2024-06-01 |
What the finished NCT04549246 record still lists
NCT04549246 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 83 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Spatially Fractionated Radiation (GRID) Therapy is the first listed.
NCT04549246 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04549246 about?
NCT04549246 is a clinical study titled "Grid Therapy for Tumors of the Head, Neck, Thorax, Abdomen, Pelvis and Extremities.". This study is an observational registry study evaluating the clinical outcomes of grid therapy. Subjects will be screened at outpatient clinic visit appointments and interested qualified subjects will be consented and offered participation in this study. Once consent has been obtained, baseline adve...
What is the current status of trial NCT04549246?
This trial is currently completed. The enrollment target is 83 participants. The study started on 2020-06-18. Estimated completion is 2024-06-01.
What interventions are being tested in trial NCT04549246?
The interventions under investigation include: Spatially Fractionated Radiation (GRID) Therapy (RADIATION).
Who is sponsoring clinical trial NCT04549246?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI